Course of COVID-19 Pneumonia in a Kidney Transplant Patient Receiving Eculizumab

Abstract

Keywords

clinical outcomes atypical hemolytic uremic syndrome renal transplant immunology infection viral infection eculizumab

Get full access to this article

View all access options for this article.

References

Maggiore

Abramowicz

Crespo

, et al. How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion. Nephrol Dial Transplant. 2020;35(6):899–904. doi:10.1093/ndt/gfaa130

Laurence

Mulvey

Seshadri

, et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020;219:108555. doi:10.1016/j.clim.2020.108555

Mastellos

Pires da Silva

BGP

Fonseca

BAL

, et al. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin Immunol. 2020;220:108598. doi:10.1016/j.clim.2020.108598

Trimarchi

Gianserra

Lampo

Monkowski

Lodolo

. Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome. Clin Kidney J. 2020;13(5):739–741. doi:10.1093/ckj/sfaa166

Araten

Belmont

Schaefer-Cutillo

Iyengar

Mattoo

Reddy

. Mild clinical course of COVID-19 in 3 patients receiving therapeutic monoclonal antibodies targeting c5 complement for hematologic disorders. Am J Case Rep. 2020;21:e927418. doi:10.12659/AJCR.927418